Global Search | Novartis

Hide Filters

Showing 2680 results

Press Release / Nov 02, 2018

Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology

Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2-…
Press Release / Nov 05, 2018

Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms

26 potential blockbusters in confirmatory development[1]. 13 projects in clinical development across Cell, Gene & Radioligand therapies. 60 major submissions[2] planned from 2019 to 2021…
Press Release / Nov 02, 2018

Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs

Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…
Press Release / Nov 11, 2018

New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker…
Press Release / Nov 16, 2018

Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer

Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs. endocrine therapy alone[1] CHMP opinion is…
Key Release / Nov 13, 2018

Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London

Basel, November 13, 2018 - Novartis today announced that Alcon has filed an initial Form 20-F registration statement with the US Securities and Exchange Commission (SEC) in relation to the previously…
Press Release / Nov 16, 2018

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication

Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation Approval…
Press Release / Nov 20, 2018

Novartis rises to second place in 2018 Access to Medicine Index

Company leads the industry in access-to-medicine management thanks to long- term commitment, as well as ongoing innovation in access to healthcare Novartis moves up one position from number 3 in…
Press Release / Nov 20, 2018

Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder

reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of…
Press Release / Nov 23, 2018

Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease

Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65…